- Home
- Companies
- Kadimastem Ltd.
- Products
- IsletRx for Diabetes
IsletRx for Diabetes
We Have Reached Successful Pre-clinical results of our cell Therapy Treatment for Insulin-Dependent Diabetes. Diabetes mellitus is a chronic disorder characterized by high blood glucose levels and glucose intolerance, due to insulin deficiency, impaired effectiveness of insulin action, or both. Diabetes is classified on the basis of cause and clinical presentation into two major types: type 1 and type 2 diabetes. In Type 1 diabetes pancreatic islets are destroyed, causing deficiency in insulin production and secretion. It currently requires daily glucose monitoring and injection of exogenous insulin. Type 2 diabetes results from insulin resistance, in which the body fails to use insulin properly.
Kadimastem is focused on the generation and manufacturing of pancreatic insulin secreting islets (IsletRx) from embryonic stem cells for the treatment of insulin dependent diabetes such as Type 1 Diabetes. This program is in pre-clinical phase and we are moving fast down the regulatory path to start human trials
Kadimastem`s product IsletRx contains pancreatic islet cells which produce and secrete insulin and glucagon in response to blood glucose levels. IsletRx is produced utilizing proprietary method of the Company, which includes a unique stage for enrichment for functionally active cells using newly specific cell surface biomarkers. In addition, a unique micro-encapsulation technology, integrated within IsletRx, protects the islet cells from the host immune system, without the need for potentially toxic immunosuppressive drug treatment and allows for prolonged therapeutic effect, demonstrated in pre-clinical studies. IsletRx is intended for the treatment of Insulin Dependent Diabetes, aiming to free patients from continuous monitoring of blood sugar levels and repeated insulin injections.
The Company reports that study objectives have been achieved, as study results show safe delivery of IsletRx and demonstrate efficacy manifested by prolonged normalized blood sugar levels in treated immunocompetent diabetic mice throughout the duration of the preclinical study (3 months). Furthermore, no disease or treatment related complications were observed, and all treated animals remained healthy throughout study duration. In comparison, a control group of non-treated diabetic mice presented severe hyperglycemia, leading to the death of the non-treated mice within 40 days.